TY - JOUR
T1 - Zonisamide, a novel antiepileptic agent
AU - Leppik, Ilo E
PY - 1999/11/19
Y1 - 1999/11/19
N2 - Zonisamide (Zonegran(TM)) is a new, broad-spectrum antiepileptic which has demonstrated a high degree of effectiveness in treating both localization-related and generalized epilepsies, as well as progressive myoclonic epilepsy syndromes. The pharmacokinetic profile of zonisamide is particularly favorable, including rapid and full absorption, a long half- life, and relatively low levels of protein binding. Zonisamide has been evaluated in a total of 7 randomized controlled and open-label studies, with clinical efficacy that is equivalent or superior to that of standard antiepileptic drugs such as carbamazepine and valproate. Administered at an adult dosage of 400-600 mg in two divided daily doses, zonisamide has demonstrated a good safety profile in wide clinical use. This new agent is a significant therapeutic advance, expanding the available treatment options for both adults and children with epilepsy.
AB - Zonisamide (Zonegran(TM)) is a new, broad-spectrum antiepileptic which has demonstrated a high degree of effectiveness in treating both localization-related and generalized epilepsies, as well as progressive myoclonic epilepsy syndromes. The pharmacokinetic profile of zonisamide is particularly favorable, including rapid and full absorption, a long half- life, and relatively low levels of protein binding. Zonisamide has been evaluated in a total of 7 randomized controlled and open-label studies, with clinical efficacy that is equivalent or superior to that of standard antiepileptic drugs such as carbamazepine and valproate. Administered at an adult dosage of 400-600 mg in two divided daily doses, zonisamide has demonstrated a good safety profile in wide clinical use. This new agent is a significant therapeutic advance, expanding the available treatment options for both adults and children with epilepsy.
UR - http://www.scopus.com/inward/record.url?scp=0032726247&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032726247&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:0032726247
SN - 0741-2320
VL - 17
SP - 181
EP - 195
JO - Today's Therapeutic Trends
JF - Today's Therapeutic Trends
IS - 2
ER -